Silexion Therapeutics (SLXN) announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the ...

Maxim lowered the firm’s price target on Silexion Therapeutics (SLXN) to $5 from $9 and keeps a Buy rating on the shares after its Q4 results.

Significant progress in preclinical pipeline targeting KRAS-driven solid tumor cancers with systemic administration ...

The ordinary s NEW YORK, January 29, 2025--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape ...

Silexion's SIL204 reduced tumor growth and metastases in pancreatic cancer models, showing strong efficacy across KRAS mutation profiles in preclinical studies.

(RTTNews) - Silexion Therapeutics (SLXN) announced positive data from preclinical studies of SIL204, its RNA interference (RNAi) therapy, in orthotopic pancreatic cancer models. These findings ...

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...